What type of biologic drugs does Ustekinumab belong to?

Ustekinumab is a biologic drug that targets specific signaling pathways of the immune system. It belongs to the anti-interleukin (12/23) monoclonal antibody class. It modulates the immune response and reduces the occurrence of inflammatory reactions by blocking two key inflammatory mediators, IL-12 and IL-23. IL-12 and IL-23 play a central role in the pathogenesis of various autoimmune diseases. Ustekinumab can effectively control the progression of the disease by targeting these two cytokines.

As a humanizedIgG1κ monoclonal antibody, ustekinumab is specifically designed to neutralizeIL-12 This combination inhibits their binding to receptors and blocks the transmission of relevant inflammatory signals. Compared with traditional immunosuppressants, ustekinumab has a more precise mechanism of action and can reduce the risk of side effects caused by systemic immunosuppression. Its precise targeting properties make treatment more effective and safer, and it has become an important member of biologic drugs in recent years.

Ustekinumab is mainly used to treat a variety of immune-mediated diseases, especially in inflammatory bowel diseases such as moderate to severe plaque psoriasis, psoriatic arthritis, and Crohn's disease. It relieves inflammatory symptoms of skin and joints and improves patients' quality of life by regulating abnormally active immune responses. At the same time, due to its long half-life, ustekinumab usually adopts a dosing schedule with longer intervals to facilitate patient use and improve compliance.

In general, ustekinumab, as an antiIL-12/23 monoclonal antibody, belongs to the category of biological drugs that target immune regulation. It achieves effective control of a variety of autoimmune diseases by precisely inhibiting key inflammatory mediators with relatively minor side effects. With the development of biotechnology and the deepening of clinical application, ustekinumab has become increasingly prominent in the treatment of immune-related diseases and has become an important treatment option for many patients.

Reference materials:https://www.drugs.com/donanemab.html